Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In this study, more than 12,000 patients 18 years and older with hospitalization for extremity fracture were randomized to LWMH or aspirin. Rates of DVT were 1.7% and 2.5%, respectively. PE, bleeding complications, and other SAEs were similar across groups. Death occurred in 0.73% and 0.78% respectively for LWMH and aspirin.
Hematology January 25th 2023
JAMA Network
The risk of symptomatic intracranial hemorrhage was lower among the 832 patients receiving direct oral anticoagulant treatment in this cohort study involving 33,207 patients with ischemic stroke who received intravenous thrombolysis at 64 centers in Europe, Asia, Australia, and New Zealand when compared to controls who received no anticoagulation. This outcome held true across subgroups and various selection methodologies.
Cardiology January 18th 2023
ACP Internist
A 61-year-old woman taking methotrexate for RA, which has been stable for several years, has new monoclonal protein discovered on routine follow-up. Physical and routine labs are normal. Electrophoresis displays an IgG κ monoclonal protein spike of 0.8 g/dL. What is the proper follow-up?
Family Medicine/General Practice January 11th 2023
Blood
The first treatment for light-chain amyloidosis was approved by the FDA in 2021. Daratumumab-based regimens produce profound hematologic and organ responses, providing a new therapeutic foundation. Early detection, correct fibril typing, the challenges of the very advanced patient, and the lack of therapies to remove amyloid deposits are all being researched but remain elusive.
Hematology December 12th 2022
MedPage Today
In the US, reports of COVID-related clots have declined. But social media posts in the UK indicate a rise there – and typically what the UK reports is a harbinger of what is coming to the US.
Allergy & Immunology November 9th 2022
Hematology Advisor
This “Clinician POV” with Joshua Strauss, MD, a hematologist-oncologist with Advanced Care Hematology & Oncology Associates in New Jersey, discusses the available formulations of parenteral iron and their respective risks for hypophosphatemia, patient- and disease-related factors of the condition, administration of the formulations, monitoring, and more.
Endocrinology, Diabetes, Metabolism October 19th 2022